摘要
摘要目的观察麝香通心滴丸治疗气虚血瘀型冠心病心绞痛的临床疗效.方法将符合纳入标准的气虚血瘀型冠心病心绞痛１８０例,随机分为两组各９０例.对照组给予消心痛片,１０mg/次,３次/d;心痛定片,１０mg/次,３次/d;拜阿司匹林,１００mg/次,１次/d;治疗组在对照组治疗的基础上口服麝香通心滴丸,一次２丸,一日３次,两组均连续治疗２８d.观察两组患者的临床疗效,比较两组察心绞痛症状、心电图疗效以及血脂总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL－C)、低密度脂蛋白胆固醇(LDL－C)、血液流变指标的变化.结果两组治疗后心绞痛发作频率(次/周)及发作持续时间(min/次)均缩短,两组比较差异有统计学意义(P＜０．０５).治疗组和对照组的心绞痛有效率分别为９０％、８０％,两组比较差异有统计学意义(P＜０．０５).两组心电图疗效比较,治疗组优于对照组(P＜０．０５).治疗后,两组患者的TC和TG水平均较治疗前有显著降低,同组治疗前后差异有统计学意义(P＜０．０５),治疗组低于对照组,组间比较差异有统计学意义(P＜０．０５).治疗后,两组红细胞压积、全血高切黏度、全血低切黏度、血浆高切黏度、纤维蛋白原指标均有不同程度的降低,同组治疗前后比较差异均有统计学意义(P＜０．０５).治疗组上述指标均比对照组降低更加明显,两组比较差异有统计学意义(P＜０．０５).两组在并发症发生率方面未见明显差异(P＞０．０５).结论麝香通心滴丸治疗气虚血瘀型冠心病心绞痛可以明显提高其临床疗效,可能与减轻患者的心绞痛症状,改善微循环有关.关键词冠心病;心绞痛;气虚血瘀型;麝香通心滴丸CliticalResearchonShexiangTongxinDroppingPillinTreatingAnginaCoronaryAtheroscleroticHeartDisease(CHD)withQiDeftciencyandBloodStasisSyndromeAbstractObjectiveToobservetheclinicalefficiencyofShexiangTongxinDroppingPillintreatedofAnginaCoronaryAtheroscleroticHeartDisease(CHD)withQiDeftciencyandBloodStasisSyndrome．Methods１８０typeacuteCHDpatientswererandomlydividedintotreatedgrouptreatedgroup(９０cases)andcontrolgroup(９０cases),Thecontrolgroupwasgivenisosorbidedinitratetablets,１０mgatatime,threetimesaday;Nifedipinetablets,１０mgatatime,threetimesaday;aspirin,１００mgatatime,onceaday．TreatmentgroupwastreatedwithShexiangTongxinDroppingPillonthebasisofthecontrolgroup,twopillsatatime,threetimesaday．Thetwogroups??treatmentcoursewas２８days．testForallthepatients,anginapectorissymptoms,ECG,syndromeandsignswereallobserved．Inaddition,hemorheologicalindexesandbloodlipid(TC,TG,LDL－C,HDL－C)weretestedbeforeandafterthetreatment．ResultsAftertreatment,anginafrequency(times/week)andattacklasttime(min)/timeofthetwogroupswereshortened,therewasstaististicaldifferencebetweenthetwogroups(p＜０．０５)．Theclinicalcurativeeffectiveofanginapectorissymptomsoftreatedgroupandcontrolgroupwere９４．１２％and９１．１８％respectly．Similarlythereweresignificantdifferencesamongthetwogroups(P＜０．０５)．Theelectrocardiogramefficienciesinthetreatmentgroupwasclearlybetterthanthecontrolgroup(P＜０．０５)．BothgroupswereimprovedonTCandTGcomparedwithbeforetreated(P＜０．０５),andthetreatmentgroupwasbetterthanthatofcontrolgroup(P＜０．０５)．Reviewoftheindexesofhemorrheology,GaoQiequanbloodviscosity,lowshearbloodviscosity,plasmaviscosity,hemaＧtocritanderythrocytesedimentationrateinbothgroupsdecreased,andtherewassignificantdifferenceamongthetwogroups(p＜０．０５)．Therewasnosignificantdifferenceinincidenceofcomplicationsbetweenthetwogroups(p＞０．０５)．ConclusionShexiangTongxinDroppingPillintreatedofAnginaCoronaryAtheroscleroticHeartDisease(CHD)withQiDeftciencyandBloodStasisSyndromecanobviouslyimprovetheclinicalcurativeeffect,．ThemechanismmayberelatedtorelievingsymptomsinpatientswithanginapectorisKe,iymwproorvdisngmicrocirculation．Coronanyheartdisease;anginapectoris;QiDeftciencyandBloodStasisSyndrome;ShexiangTongxinDroppingPill中图分类号R５６２．２文献标识码B文章编号１００８－６３１５(２０１５)１２－０５７３－０２
出版日期
2015年12月22日（中国期刊网平台首次上网日期，不代表论文的发表时间）
